All In MedTech

FDA Clearance Tracker · K231776

Cell-Free DNA BCT

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Jul 26, 2024 (this decision)Source: openFDAMethods & limitations

510(k)

The decision

FDA number
K231776
Device name
Cell-Free DNA BCT
Applicant
Streck, Inc.
Applicant location
La Vista, NE
Received
Jun 16, 2023
Decided
Jul 26, 2024
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 862.1676

Every decision under product code QMA

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code QMA. The earliest in FDA's data is DEN200001, decided Aug 7, 2020.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

  • FDA database record for K231776
  • The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Streck, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.